Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 168 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbohydrate load Clear all
Completed Phase 2 Interventional

Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT

NCT00350181
View directory record Official record
Conditions
Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
Interventions
Sirolimus, MMF, BCNU, VP-16, CY, FTBI, BU
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 27, 2026, 1:48 PM EDT
Terminated Phase 1 Interventional

A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer

NCT02963051
View directory record Official record
Conditions
Prostate Cancer
Interventions
Copper, Disulfiram, Copper gluconate
Drug
Lead sponsor
Daniel George, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Oct 27, 2026, 1:48 PM EDT
Active, not recruiting Phase 1 Interventional

RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)

NCT07492316
View directory record Official record
Conditions
Recurrent Medulloblastoma
Interventions
Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)
Biological
Lead sponsor
University of Florida
Other
Eligibility
4 Years to 39 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 1:48 PM EDT
Not listed Phase 2 Interventional

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

NCT03412643
View directory record Official record
Conditions
HER2-negative Breast Cancer
Interventions
Doxorubicin, Cyclophosphamide, Weekly Paclitaxel, Trastuzumab, Pertuzumab, Celcuity CELx HSF
Drug · Diagnostic Test
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
43
States / cities
Colton, California • Miami Beach, Florida • Orlando, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Not applicable Interventional

A Pilot Study of a Low Glycemic Load Diet in Adults With Cystic Fibrosis

NCT04519853
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis With Intestinal Manifestations
Interventions
Low Glycemic Load Diet
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 27, 2026, 1:48 PM EDT
Terminated Not applicable Interventional Results available

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

NCT01897441
View directory record Official record
Conditions
Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Cyclophosphamide, Cytology Specimen Collection Procedure, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Trastuzumab, Endocrine therapy
Drug · Other · Biological
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Not applicable Interventional

Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins

NCT00593424
View directory record Official record
Conditions
Hypertriglyceridemia, Diabetes Mellitus
Interventions
Low Fat/High Carbohydrate, High Monounsaturated Fat/Low Carbohydrate
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VA106483 Dose Response in Females

NCT01171391
View directory record Official record
Conditions
Nocturia
Interventions
VA106483, Placebo
Drug · Other
Lead sponsor
Vantia Ltd
Industry
Eligibility
40 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Endothelial Function in Obese Adolescents

NCT01879033
View directory record Official record
Conditions
Insulin Resistance, Glucose Intolerance, Obesity, Atherosclerosis
Interventions
Reactive hyperemia peripheral artery tonometry (Rh-PAT), Blood levels for glucose, insulin, lipids and adipocytokines
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 18 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

NCT00446030
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Docetaxel, Doxorubicin, Carboplatin, Cyclophosphamide, Trastuzumab, Bevacizumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Phase 1 Interventional

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

NCT00671697
View directory record Official record
Conditions
Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
Interventions
Arsenic Trioxide, Decitabine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 27, 2026, 1:48 PM EDT
Completed No phase listed Observational

Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients

NCT02427932
View directory record Official record
Conditions
Drug Metabolism During Pregnancy
Interventions
Ampicillin, Ampicillin and Gentamicin, Gentamicin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 27, 2026, 1:48 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

CoEnzyme Q10 in Statin Myopathy

NCT01140308
View directory record Official record
Conditions
Statin Myopathy
Interventions
CoEnzyme Q10, Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
20 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 27, 2026, 1:48 PM EDT
Terminated Phase 4 Interventional Results available

Vitamin D Supplementation for Treatment of Heart Failure

NCT01230307
View directory record Official record
Conditions
Heart Failure
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 18, 2016 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Carbohydrates and Related Biomarkers

NCT00622661
View directory record Official record
Conditions
Healthy, Overweight
Interventions
Low Glycemic Load Diet, High Glycemic Load Diet
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 5, 2012 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Thermic & Lipemic Properties of Dietary Carbohydrates

NCT01354574
View directory record Official record
Conditions
Exogenous Obesity, Dietary Modification
Interventions
High Glycemic Index meals, Low Glycemic Index meals
Other
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 48 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2011 · Synced Oct 27, 2026, 1:48 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

NCT05436418
View directory record Official record
Conditions
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
Interventions
Melphalan, Sirolimus, Total Body Irradiation (TBI), Cyclophosphamide, Mycophenolate Mofeti, Fludarabine, Allogeneic HSCT, Mesna, Filgrastim
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
2
States / cities
Duarte, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 1:48 PM EDT
Terminated Phase 3 Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant

NCT03960008
View directory record Official record
Conditions
Hepatocellular Carcinoma, HCC
Interventions
Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
Radiation · Procedure · Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Burlington, Massachusetts • Rochester, Minnesota • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 27, 2026, 1:48 PM EDT
Recruiting Phase 2Phase 3 Interventional

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

NCT03013998
View directory record Official record
Conditions
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Interventions
Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis, Daunorubicin (BAML-16-001-S1), Cytarabine (BAML-16-001-S1), Azacitidine (BAML-16-001-S2), AG-221 (BAML-16-001-S3), Azacitidine (BAML-16-001-S3), Entospletinib (BAML-16-001-S4), Azacitidine (BAML-16-001-S4), Entospletinib (BAML-16-001-S5), Decitabine (BAML-16-001-S5), Entospletinib (BAML-16-001-S6), Daunorubicin (BAML-16-001-S6), Cytarabine (BAML-16-001-S6), Pevonedistat (BAML-16-001-S9), Azacitidine (BAML-16-001-S9), AG-120 (BAML-16-001-S16), Azacitidine (BAML-16-001-S16), Gilteritinib (BAML-16-001-S8 Group 1), Decitabine (BAML-16-001-S8 Group 1), AZD5153 (BAML-16-001-S10), Venetoclax (BAML-16-001-S10), TP-0903 (BAML-16-001-S14), Decitabine (BAML-16-001-S14), Decitabine (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S8 Group 2), AZD5991 (BAML-16-001-S18), Azacitidine (BAML-16-001-S18), SNDX-5613 (BAML-16-001-S17), Azacitidine (BAML-16-001-S17), Venetoclax (BAML-16-001-S17), Gilteritinib (BAML-16-001-S8 Group 2), Venetoclax (BAML-16-001-S12 Arm A), Azacitidine (BAML-16-001-S12 Arm A), Venetoclax (BAML-16-001-S12 Arm B), Azacitidine (BAML-16-001-S12 Arm B), ZE46-0134 (BAML-16-001-S21 Group 1), ficlatuzumab (BAML-16-001-S24), Azacitidine (BAML-16-001-S24), Venetoclax (BAML-16-001-S24), ZE46-0134 (BAML-16-001-S21 Group 2), Bleximenib (BAML-16-001-S25/HO181), Cytarabine (BAML-16-001-S25/HO181), Daunorubicin or Idarubicin (BAML-16-001-S25/HO181), Placebo (BAML-16-001-S25/HO181), Revumenib (BAML-16-001-S26/HO177), Placebo (BAML-16-001-S26/HO177)
Biological · Other · Drug
Lead sponsor
Beat AML, LLC
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2032
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 27, 2026, 1:48 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

NCT00140140
View directory record Official record
Conditions
Stage IV (Metastatic) Breast Cancer
Interventions
ABI-007, vinorelbine, Trastuzumab, G-CSF
Drug · Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 27, 2026, 1:48 PM EDT
Active, not recruiting Not applicable Interventional

Functional Outcomes From Diets in Multiple Sclerosis

NCT05327322
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Glycemic load, Calorie restriction, Behavioral support
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes

NCT04416204
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
glycogen loading, No Glycogen Loading
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
30 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Phase 2 Interventional Results available

Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

NCT01570036
View directory record Official record
Conditions
Breast Cancer
Interventions
Herceptin, NeuVax vaccine, GM-CSF
Drug
Lead sponsor
George E. Peoples
Industry
Eligibility
18 Years and older · Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
29
States / cities
Beverly Hills, California • Santa Monica, California • Santa Rosa, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 27, 2026, 1:48 PM EDT
Completed Not applicable Interventional Results available

Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)

NCT01184898
View directory record Official record
Conditions
AML
Interventions
Sirolimus, Mitoxantrone, Etoposide, Cytarabine
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 27, 2026, 1:48 PM EDT